Together, these findings demonstrate a mechanism of AMPK downregulating H3K9me2 modification and provide new insights of PHF2 as the potential epigenetic target in lung cancer metastasis, thereby promoting the clinical application of metformin into suppressing tumor development. This evidence concerns the gene PRKAA2 and lung cancer.